Kamby C, Ejlertsen B, Andersen J, Birkler N E, Rytter L, Zedeler K, Rose C
Department of Oncology ONA, Finsen Institute, Rigshospitalet, Copenhagen, Denmark.
Acta Oncol. 1988;27(6A):715-9. doi: 10.3109/02841868809091774.
Of the 3,802 patients enrolled in the DBCG 77 protocols, 863 developed clinical recurrence within a median follow-up time of 4.9 years (range 2.0-7.0). More than 69% of these had their first recurrence confined to a single anatomical site and 12% had more than two metastatic sites. The most common sites were bone (35%), lung (23%), skin (22%), and regional lymph nodes (16%). The observation period after first recurrence was 3.6 years (range 0.8-6.4). Survival after recurrence was significantly related both to the location and the number of metastases. Patients who were given adjuvant chemotherapy (n = 134) had significantly fewer metastatic sites and significantly more frequent liver metastases than untreated patients (n = 50). Patients who received adjuvant tamoxifen (n = 154) had the same number of metastatic sites, but more often had lung metastases than untreated patients (n = 201). These results probably reflect that metastases in different anatomical locations differ with respect to sensitivity to antineoplastic treatments.
在参加丹麦乳腺癌协作组（DBCG）77方案的3802例患者中，863例在中位随访时间4.9年（范围2.0 - 7.0年）内出现临床复发。其中超过69%的患者首次复发局限于单个解剖部位，12%的患者有两个以上转移部位。最常见的部位是骨（35%）、肺（23%）、皮肤（22%）和区域淋巴结（16%）。首次复发后的观察期为3.6年（范围0.8 - 6.4年）。复发后的生存率与转移部位和转移数量均显著相关。接受辅助化疗的患者（n = 134）转移部位明显少于未治疗患者（n = 50），但肝转移更为常见。接受辅助他莫昔芬治疗的患者（n = 154）转移部位数量与未治疗患者（n = 201）相同，但肺转移更为常见。这些结果可能反映出不同解剖部位的转移对抗肿瘤治疗的敏感性不同。
